​

Neurocrine Biosciences (NBIX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

NBIX Stock Forecast

Neurocrine Biosciences (NBIX) stock forecast, based on 37 Wall Street analysts, predicts a 12-month average price target of $203.76, with a high of $230.00 and a low of $165.00. This represents a 31.34% increase from the last price of $155.14.

$100 $130 $160 $190 $220 $250 High: $230 Avg: $203.76 Low: $165 Last Closed Price: $155.14

NBIX Stock Rating

Neurocrine Biosciences stock's rating consensus is Buy, based on 37 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 32 Buy (86.49%), 5 Hold (13.51%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 37 0 5 32 Strong Sell Sell Hold Buy Strong Buy

NBIX Price Target Upside V Benchmarks

TypeNameUpside
StockNeurocrine Biosciences31.34%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts42051
Avg Price Target$190.75$199.35$188.59
Last Closing Price$155.14$155.14$155.14
Upside/Downside22.95%28.50%21.56%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 264194--27
Aug, 264194--27
Jul, 264214--29
Jun, 264204--28
May, 264194--27
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 08, 2026Brian AbrahamsRBC Capital$198.00$155.6627.20%27.63%
Aug 13, 2026Bernstein$218.00$156.4939.31%40.52%
Aug 13, 2026Morgan Stanley$182.00$156.4916.30%17.31%
Aug 13, 2026Deutsche Bank$165.00$156.495.44%6.36%
Aug 03, 2026Wedbush$194.00$170.0614.08%25.05%
Aug 03, 2026Andrew FeinH.C. Wainwright$215.00$166.8028.90%38.58%
Aug 03, 2026Sumant KulkarniCanaccord Genuity$210.00$166.8025.90%35.36%
Jul 31, 2026Morgan Stanley$196.00$167.3817.10%26.34%
Jul 31, 2026David HoangDeutsche Bank$190.00$165.9314.51%22.47%
Jul 31, 2026Needham$204.00$185.509.97%31.49%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 08, 2026RBC CapitalOutperformOutperformhold
Sep 03, 2026CitigroupBuyBuyhold
Aug 03, 2026WedbushOutperformOutperformhold
Aug 03, 2026H.C. WainwrightBuyBuyhold
Jul 31, 2026CitigroupBuyBuyhold
Jul 31, 2026Cowen & Co.BuyBuyhold
Jul 31, 2026Deutsche BankHoldHoldhold
Jul 31, 2026Cantor FitzgeraldOverweightOverweighthold
Jul 31, 2026NeedhamBuyBuyhold
Jul 31, 2026Piper SandlerOverweightOverweighthold

Financial Forecast

EPS Forecast

$0 $4 $8 $12 $16 $20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.95$1.61$2.56$3.40$4.81---
Avg Forecast$1.78$2.22$2.56$4.05$6.40$8.65$11.24$14.00
High Forecast$1.87$2.34$2.94$4.34$7.44$11.63$15.31$14.86
Low Forecast$1.66$2.05$1.72$3.74$4.77$6.06$7.52$12.83
Surprise %-46.63%-27.48%--16.05%-24.84%---

Revenue Forecast

$1B $2B $2B $3B $4B $5B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$1.13B$1.49B$1.89B$2.36B$2.86B---
Avg Forecast$1.14B$1.48B$1.89B$2.36B$2.77B$3.24B$3.68B$4.19B
High Forecast$1.18B$1.55B$1.90B$2.37B$2.84B$3.26B$3.71B$4.38B
Low Forecast$1.08B$1.40B$1.77B$2.34B$2.58B$3.22B$3.65B$3.92B
Surprise %-0.35%0.29%-0.12%-0.11%3.23%---

Net Income Forecast

$-2B $-800M $-100M $600M $1B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$89.60M$154.50M$249.70M$341.30M$478.60M---
Avg Forecast$110.42M$4.14M$249.70M$385.90M$637.97M$898.75M$1.20B$1.41B
High Forecast$138.10M$25.12M$1.67B$438.60M$751.03M$1.18B$1.55B$1.50B
Low Forecast$82.73M$-16.85M$-1.17B$378.03M$482.22M$611.63M$759.47M$1.30B
Surprise %-18.85%3635.85%--11.56%-24.98%---

NBIX Forecast FAQ

Is Neurocrine Biosciences stock a buy?

Neurocrine Biosciences stock has a consensus rating of Buy, based on 37 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 32 Buy, 5 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Neurocrine Biosciences is a favorable investment for most analysts.

What is Neurocrine Biosciences's price target?

Neurocrine Biosciences's price target, set by 37 Wall Street analysts, averages $203.76 over the next 12 months. The price target range spans from $165 at the low end to $230 at the high end, suggesting a potential 31.34% change from the previous closing price of $155.14.

How does Neurocrine Biosciences stock forecast compare to its benchmarks?

Neurocrine Biosciences's stock forecast shows a 31.34% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Neurocrine Biosciences over the past three months?

  • September 2026: 14.81% Strong Buy, 70.37% Buy, 14.81% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 14.81% Strong Buy, 70.37% Buy, 14.81% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 13.79% Strong Buy, 72.41% Buy, 13.79% Hold, 0% Sell, 0% Strong Sell.

What is Neurocrine Biosciences’s EPS forecast?

Neurocrine Biosciences's average annual EPS forecast for its fiscal year ending in December 2026 is $8.65, marking a 79.83% increase from the reported $4.81 in 2025. Estimates for the following years are $11.24 in 2027, and $14 in 2028.

What is Neurocrine Biosciences’s revenue forecast?

Neurocrine Biosciences's average annual revenue forecast for its fiscal year ending in December 2026 is $3.24B, reflecting a 13.23% increase from the reported $2.86B in 2025. The forecast for 2027 is $3.68B, and $4.19B for 2028.

What is Neurocrine Biosciences’s net income forecast?

Neurocrine Biosciences's net income forecast for the fiscal year ending in December 2026 stands at $898.75M, representing an 87.79% increase from the reported $478.6M in 2025. Projections indicate $1.2B in 2027, and $1.41B in 2028.